World's Best Scientists 2026 revealed!
A. van Oosterom

A. van Oosterom

Overview

A. van Oosterom was affiliated with KU Leuven in Belgium during their academic career. Their work contributed to various aspects of scientific research, though specific details about publications, research topics, and collaborations remain limited in the available data.

There are no recorded recent papers listed for A. van Oosterom, which means that details such as the titles, years of publication, and venues of their research articles are not provided. Similarly, there is no information about frequent co-authors or regular publication venues, so patterns of collaboration and common platforms for their work cannot be described.

The available data does not include any book publications, leaving their involvement in longer form academic writing or editorial projects undocumented. The scientist's main fields of study and subfields are also not specified, making it difficult to pinpoint the specific academic disciplines or specialized areas they focused on throughout their career.

Likewise, no main topics of work are recorded, so it is not possible to outline the subjects or problems that they explored or contributed to. No awards have been listed, so there is no documentation of formal recognition or distinctions granted to them during their professional life.

The absence of detailed information regarding these aspects indicates that A. van Oosterom either maintained a low profile in published records accessible to this dataset or their work is documented elsewhere without being aggregated here. The data confirms that they are deceased, concluding their body of work as historical rather than ongoing.

Best Publications

  • Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

    George D Demetri;Allan T van Oosterom;Christopher R Garrett;Martin E Blackstein

  • Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial*

    Jaap Verweij;Paolo G. Casali;John Zalcberg;Axel LeCesne

  • Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924

    Cora N. Sternberg;P. H.M. De Mulder;J. H. Schornagel;C. Théodore

  • Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.

    M. Van Glabbeke;A.T. van Oosterom;J.W. Oosterhuis;H. Mouridsen

  • 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).

    S. Stroobants;J. Goeminne;M. Seegers;S. Dimitrijevic

  • Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.

    J Verweij;A van Oosterom;J.-Y Blay;I Judson

  • Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

    C.N. Sternberg;P.H.M. de Mulder;J.H. Schornagel;C. Theodore

  • Outcomes of cancer treatment for technology assessment and cancer treatment guidelines

    John Fetting;Paul Anderson;Harrison Ball;John Benear

  • Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial

    A. Le Cesne;J.Y. Blay;I. Judson;A. Van Oosterom

  • Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma : a study by the EORTC Soft Tissue and Bone Sarcoma Group

    Ian R Judson;John A Radford;Maggie A Harris;Jean-Yves Blay

  • On the numerical accuracy of the boundary element method (EEG application)

    J.W.H. Meijs;O.W. Weier;M.J. Peters;A. Van Oosterom

  • Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.

    J P Neijt;W W ten Bokkel Huinink;M E van der Burg;A T van Oosterom

  • A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup.

    V H Bramwell;M Burgers;R Sneath;R Souhami

  • The Solid Angle of a Plane Triangle

    A. Van Oosterom;J. Strackee

  • Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.

    H Wildiers;G Guetens;G De Boeck;E Verbeken

  • Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients.

    L. Y. Dirix;P. B. Vermeulen;A. Pawinski;A. ProvÃ

  • Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

    F.A.L.M Eskens;H Dumez;R Hoekstra;A Perschl

  • Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.

    A. Le Cesne;I. Judson;D. Crowther;S. Rodenhuis

  • Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas

    Vivien H.C. Bramwell;H.T. Mouridsen;A. Santoro;G. Blackledge

  • RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMA

    J.P. Neijt;M.E.L. Van Der Burg;R. Vriesendorp;A.C.M. Van Lindert

Frequent Co-Authors

Jaap Verweij
Jaap Verweij Erasmus University Rotterdam
Richard Sylvester
Richard Sylvester European Organisation for Research and Treatment of Cancer
Ian Judson
Ian Judson Institute of Cancer Research
Peter B. Vermeulen
Peter B. Vermeulen University of Antwerp
Jan B. Vermorken
Jan B. Vermorken University of Antwerp
Sophie D. Fosså
Sophie D. Fosså Oslo University Hospital
Sergio Pecorelli
Sergio Pecorelli University of Brescia
Armando Santoro
Armando Santoro Humanitas University
U.R. Tjaden
U.R. Tjaden Leiden University
Dick F. Stegeman
Dick F. Stegeman Radboud University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA opens doors to a variety of rewarding online healthcare degrees and career pathways. For students interested in medication and patient care, online pharmacy school programs provide a flexible option to pursue a career as a pharmacist without compromising on quality education.

The rise of technology in healthcare has also made health informatics a fast-growing field. Pursuing a degree in health informatics equips students to manage, analyze, and secure health data for hospitals and clinics.

For those interested in administrative roles, understanding how much is medical billing and coding school costs and what programs offer can lead to a steady and in-demand position managing billing and patient records.

Finally, aspiring advanced practice nurses can explore the cheapest np school options to become nurse practitioners through affordable accredited online programs. These paths offer flexibility and strong job prospects in the dynamic field of healthcare.

Best Scientists Citing A. van Oosterom

Recently Published Articles